A Phase 1 interventional study of TLL018 tablets in Chronic Spontaneous Urticaria, sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-03-01.
Sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Chronic Urticaria with a site in China — 16 open to participants now, 20 under way, 5 of them phase 3. Chronic Urticaria · China.
Among the 34 studies in Chronic Urticaria with a site in China, this one is the 26th largest by enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2022, is one of 7 in phase 1, and was the 6th registered.
197 studies on the registry are indexed under Chronic Urticaria; 48 are open to participants now.
Browse Chronic Urticaria studies →16 of the 34 studies in Chronic Urticaria with a site in China are open now. Recruiting first, the newest first:
Novelty Nobility, Inc. · Sites in China
Ages 18–75 · Healthy volunteers
Bambusa Therapeutics · Sites in China
Ages 18–75 · Healthy volunteers
Yuhan Corporation · Sites in China, Bulgaria, Poland and 1 more country
Ages 18–75
Jemincare · Sites in China
Ages 18+
Beijing InnoCare Pharma Tech Co., Ltd. · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 25 Chronic Urticaria studies recruiting now, 11 (44%) set no upper age limit and 10 (40%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 13 · Phase 3 10
First in 2013; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 41 is below the median of 80 across 147 interventional studies indexed under Chronic Urticaria.
Median enrollment 110 across the 30 interventional studies, 270 across the 4 observational. Of the 13 that completed or were terminated, 3 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 34 have an industry lead sponsor. The 10 most frequent:
Hangzhou Highlightll Pharmaceutical Co., Ltd is the lead sponsor of 14 studies on the registry; 5 are open to participants now.
Hangzhou Highlightll Pharmaceutical Co., Ltd has 4 studies filed under Chronic Urticaria — fewer than ten, so there is no comparison to draw.
10 of the studies in Chronic Urticaria with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07402213Phase 3JemincareTrial of JYB1904 Injection in Adult Patients With Chronic Spontaneous Urticaria. | 2027-06-07 |
| NCT06604949Longbio PharmaA Study of Single Dose of LP-003 in Healthy Adult Subjects | 2026-11 |
| NCT07005713BeOne MedicinesA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants | 2026-11-30 |
| NCT07613866Chengdu Suncadia Medicine Co., Ltd.A Clinical Trial of HRS-3095 in Patients With Chronic Spontaneous Urticaria | 2026-12 |
| NCT07219615PfizerA Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults. | 2026-12-25 |
Add all 10 to your calendar (.ics) → With an account.
Among the 34 studies in Chronic Urticaria with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a randomized, double-blind, placebo-controlled, multicenter clinical trial of about 36 subjects with moderate to severe Chronic Spontaneous Urticaria.
Successfully screened subjects will be randomized in a ratio of 1:1:1. After a 4-week screening period (day -28-0), subjects will be randomly assigned to treatment for 12 weeks.
Clinical Urticaria Activity Score (UAS), dermatological Quality of Life Index (DLQI), physical exams and Laboratory tests will be performed at baseline, the end of weeks 4, 8 and 12 respectively.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TLL018 tablets 1piece,BID
Drug: TLL018 tablets
TLL018 tablets 3pieces, BID
Drug: TLL018 tablets
TLL018 placeboes 3pieces, BID
Drug: TLL018 tablets
Oral tablets administered at different doses BID daily for 12 weeks.
Also known as: TLL018 Placeboes
treatment-emergent adverse events (AEs), serious adverse events (SAEs) and discontinuation due to AEs/SAEs
Number of participants with treatment-emergent adverse events (AEs), serious adverse events (SAEs) and discontinuation due to AEs/SAEs
Time frame: From day 1 to Weeks 4
adverse events (AEs) according to severity
Number of adverse events (AEs) according to severity
Time frame: From day 1 to Weeks 4
blood pressure from baseline
Change of blood pressure from baseline
Time frame: From day 1 to Weeks 4
pulse rate from baseline
Change of pulse rate from baseline
Time frame: From day 1 to Weeks 4
respiratory rate from baseline
Change of respiratory rate from baseline
Time frame: From day 1 to Weeks 4
temperature from baseline
Change of oral temperature from baseline
Time frame: From day 1 to Weeks 4
clinical laboratory abnormalities compared to baseline
Number of participants with clinical laboratory abnormalities compared to baseline
Time frame: From day 1 to Weeks 4
ECG parameters from baseline
Change in 12-lead electrocardiogram (ECG) parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) from baseline
Time frame: From day 1 to Weeks 4
physical examination findings from baseline
Number of participants with changes in physical examination findings from baseline
Time frame: From day 1 to Weeks 4
Cmax of TLL018
Maximum observed plasma concentration (Cmax) of TLL018
Time frame: 0 hour (pre-dose - within 30 minutes prior to dosing), and at 0.5, 1, 2, 4 and 8 hours post-dose
treatment-emergent adverse events (AEs), serious adverse events (SAEs) and discontinuation due to AEs/SAEs
Number of participants with treatment-emergent adverse events (AEs), serious adverse events (SAEs) and discontinuation due to AEs/SAEs
Time frame: From week 4 to Weeks 12
adverse events (AEs) according to severity
Number of adverse events (AEs) according to severity
Time frame: From week 4 to Weeks 12
blood pressure from baseline
Change of blood pressure from baseline
Time frame: From week 4 to Weeks 12
pulse rate from baseline
Change of pulse rate from baseline
Time frame: From week 4 to Weeks 12
respiratory rate from baseline
Change of respiratory rate from baseline
Time frame: From week 4 to Weeks 12
temperature from baseline
Change of oral temperature from baseline
Time frame: From week 4 to Weeks 12
clinical laboratory abnormalities compared to baseline
Number of participants with clinical laboratory abnormalities compared to baseline
Time frame: From week 4 to Weeks 12
ECG parameters from baseline
Change in 12-lead electrocardiogram (ECG) parameters (PR Interval, QRS Complex, QT Interval, QTC Interval) from baseline
Time frame: From week 4 to Weeks 12
physical examination findings from baseline
Number of participants with changes in physical examination findings from baseline
Time frame: From week 4 to Weeks 12
UAS7 score decreased from baseline at week 4
Change in mean value of UAS7 score from baseline at week 4 when comparing TLL-018 with placebo
Time frame: Baseline to Week 4
UAS7 score decreased from baseline at week 8
Change in mean value of UAS7 score from baseline at week 8 when comparing TLL-018 with placebo
Time frame: Time Frame: Baseline to Week 8
UAS7 score decreased from baseline at week 12
Change in mean value of UAS7 score from baseline at week 12 when comparing TLL-018 with placebo
Time frame: Baseline to Week 12
DLQI score decreased from baseline at week 4
Change in mean value of DLQI score from baseline at week 4 when comparing TLL-018 with placebo
Time frame: Baseline to Weeks 4
DLQI score decreased from baseline at week 8
Change in mean value of DLQI score from baseline at week 8 when comparing TLL-018 with placebo
Time frame: Baseline to Weeks 8
DLQI score decreased from baseline at week 12
Change in mean value of DLQI score from baseline at week 12 when comparing TLL-018 with placebo
Time frame: Baseline to Weeks 12
Ran from May 2022 to primary completion in Sep 2023, 15 months.
Of 15 phase 1 interventional studies under Chronic Urticaria, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 21. This study's 15 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: TLL-018
Hangzhou Highlightll Pharmaceutical Co., Ltd →